Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hangzhou Alltest Biotech Co (688606) Fair Value & Analysis

Healthcare · CN · Market cap 3.7B CNY

Price¥43.78
Fair Value¥60.57
Upside+38.4%
Quality95/100
Evidence: Medium Range ¥45.43 – ¥75.71

Analysis

Hangzhou Alltest Biotech Co (688606) currently trades at ¥43.78, while our model-based Fair Value estimate is ¥60.57 — implying the stock looks roughly 38.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin test meters. In addition, the company offers SARS-COV-2 RT-qPCR assays, virus specimen stabilizers, and viral DNA/RNA extraction kits; and other test products. Its products are used in clinical testing, on-site testing, personal health management, and other fields. Hangzhou Alltest Biotech Co., Ltd. was founded in 2009 and is based in Hangzhou, China.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -55% EssilorLuxottica Société anonyme (ESLOF) -44% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -13% Becton, Dickinson and Company (BDX) -28% Alcon Inc (ALC) -33%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.